Paper Details

  1. Home
  2. Paper Details

Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes.

Author: BoydSteven, BurnsChristopher J, ChatwinCassandra L, CusickSusan M, DaigleDenis, HamrickJodie, JacksonRandy W, JohnKaitlyn, LiuBin, McLaughlinLisa, MesarosEugen, MoeckGreg, PevearDaniel C, PulseMark E, TroutRobert E, WeissWilliam J, XerriLuigi, ZulliAllison

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

This study describes the development of a novel oral prodrug, 36 (VNRX-7145/VNRX-5236 etzadroxil), that inhibits β-lactamases and restores the activity of the oral cephalosporin antibiotic ceftibuten against multi-drug-resistant bacteria. This compound holds promise for treating infections caused by β-lactamase-producing bacteria in an outpatient setting.
Paper Details　
Original Abstract of the Article :
A major antimicrobial resistance mechanism in Gram-negative bacteria is the production of β-lactamase enzymes. The increasing emergence of β-lactamase-producing multi-drug-resistant "superbugs" has resulted in increases in costly hospital Emergency Department (ED) visits and hospitalizatio...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311649/

データ提供：米国国立医学図書館（NLM）

Combating Antimicrobial Resistance: A New Weapon in the Fight Against Superbugs

This study tackles a critical challenge in modern medicine: antimicrobial resistance, the increasing threat of bacteria that are resistant to antibiotics. It's like facing a sandstorm of resistant bacteria, a growing danger in the desert of infectious disease. This research focuses on the development of a new oral drug, VNRX-7145, designed to combat bacteria that produce beta-lactamase enzymes, a common mechanism of resistance.

VNRX-7145: A New Hope for Treatment of Drug-Resistant Infections

This study highlights the promise of VNRX-7145 as a potential solution for treating infections caused by drug-resistant bacteria. It's like finding a hidden oasis of innovation, providing a new tool for combating the threat of superbugs. This research could revolutionize the treatment of multi-drug-resistant infections, offering a new weapon in the fight against antibiotic resistance.

The Race Against Resistance: A Call for Collaboration

This study emphasizes the urgent need for continued research and development of new antibiotics to combat the growing threat of antimicrobial resistance. It's like a race against time in the desert, striving to find new solutions before the threat of resistant bacteria becomes insurmountable. This study serves as a reminder of the importance of collaboration and innovation in combating this global health crisis.

Dr.Camel's Conclusion

This research offers a glimmer of hope in the fight against antibiotic resistance, showcasing the potential of VNRX-7145 as a new weapon in the arsenal against superbugs. It highlights the urgent need for continued research and development of novel therapies to combat this growing threat. This study emphasizes the importance of collaboration and innovation in conquering this global health challenge, securing a brighter future for the treatment of infectious diseases.

Date :
  1. Date Completed 2021-10-06
  2. Date Revised 2021-10-06
Further Info :

Pubmed ID

34191513

DOI: Digital Object Identifier

PMC8311649

Related Literature

Article Analysis
・Effects of ceftibuten
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.